ApprovalTrail

Approval · Notice of Compliance 26092 · 2021

OLIMEL 3.3% E: Notice of Compliance 26092

Issued April 19, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
26092
Date
April 19, 2021
Company
Baxter CorporationMississauga, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
To split the current OLIMEL / OLIMEL E / PeriOLIMEL E Product Monograph (PM) into OLIMEL and OLIMEL E / PeriOLIMEL E.

Products in this notice

BrandDINStatus today
OLIMEL 3.3% ENot yet assigned—
OLIMEL 4.4% ENot yet assigned—
OLIMEL 5.7% ENot yet assigned—
OLIMEL 7.6% ENot yet assigned—
PERIOLIMEL 2.5% ENot yet assigned—

Medicinal ingredients